Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Transdermal drug delivery system (TDDS) is an attractive method for drug delivery with convenient application, less first-pass effect, and fewer systemic side effects. Among all generations of TDDS, transdermal nanocarriers show the greatest clinical potential because of their non-invasive properties and high drug delivery efficiency. However, it is still difficult to design optimal transdermal nanocarriers to overcome the skin barrier, control drug release, and achieve targeting. Hence, surface modification becomes a promising strategy to optimize and functionalize the transdermal nanocarriers with enhanced penetration efficiency, controlled drug release profile, and targeting drug delivery. Therefore, this review summarizes the developed transdermal nanocarriers with their transdermal mechanism, and focuses on the surface modification strategies via their different functions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196818 | PMC |
| http://dx.doi.org/10.3390/molecules26113093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intelligent transdermal nanoparticles as synergizing advanced delivery systems for precision therapeutics.
Mater Today Bio
October 2025
Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Zhejiang Chinese Medical University, 75 Jinxiu Road, Wenzhou, 325000, China.
Transdermal drug delivery systems (TDDS) represent a non-invasive approach to achieve controlled drug release through the skin barrier, offering stable plasma concentrations while avoiding gastrointestinal and hepatic metabolism. However, the skin barrier poses physical challenges, making it difficult for most drugs to penetrate deep tissues using TDDS. This review systematically summarizes the research progress in nanocarrier design, physical technology application, and artificial intelligence (AI)-driven TDDS optimization design aimed at overcoming the key problem of skin barrier penetration.
View Article and Find Full Text PDFTailored transethosomal systems for tadalafil transdermal delivery: Impact of Phosal and edge activators on skin permeation and cellular uptake.
Int J Pharm X
December 2025
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Tadalafil (TDLF), a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and extensive first-pass metabolism, which limits its therapeutic efficacy. We developed Phosal-based transethosomes (TrEthOs) to overcome these challenges, thereby enhancing transdermal delivery. A Box-Behnken design was employed to optimize the formulation by evaluating the effects of Phosal type, polyethylene glycol (PEG) 400 concentration, and cholesterol content.
View Article and Find Full Text PDFAdvances in Transdermal Delivery Systems for Treating Androgenetic Alopecia.
Pharmaceutics
July 2025
State Key Laboratory of Natural Medicines, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, China.
Androgenetic alopecia (AGA) is the most prevalent form of alopecia areata. Traditional treatment options, including minoxidil, finasteride, and hair transplantation, have their limitations, such as skin irritation, systemic side effects, invasiveness, and high costs. The transdermal drug delivery system (TDDS) offers an innovative approach for treating AGA by administering medications through the skin to achieve localized and efficient delivery while overcoming the skin barrier.
View Article and Find Full Text PDFCubosomes in non-oral drug delivery: Advancing precision therapeutics from bench to bedside.
Int J Pharm
August 2025
Maliba Pharmacy College, Uka Tarsadia University, Surat 394350, India; School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales 2052, Australia. Electronic address:
Cubosomes are advanced nanostructured lipid carriers characterized by their internal bicontinuous cubic phases, which enable the simultaneous encapsulation of both hydrophilic and lipophilic therapeutics. Their unique architecture imparts superior bioadhesion, sustained drug release, and enhanced mucosal and transdermal permeability, making them promising candidates for non-oral drug delivery. This review provides a comprehensive analysis of cubosome design strategies, fabrication methodologies, and functional performance across various administration routes, including transdermal, ocular, pulmonary, parenteral, and intranasal.
View Article and Find Full Text PDFA trilayer microneedle patch for transdermal delivery of the peptide salmon calcitonin for osteoporosis therapy.
J Control Release
August 2025
School of Pharmacy, Queen's University Belfast, UK. Electronic address:
Lipid-based nanocarrier systems have multiple advantages, including biocompatibility, biodegradability and drug loading capacity. Combining these findings with the concept of dissolving microneedles (MNs) would aid in the efficient delivery of peptides and improve therapeutic outcomes. Thus, MN-mediated transdermal delivery was explored for the delivery of salmon calcitonin (sCT).
View Article and Find Full Text PDF